Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/39040
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHartung, H. -P.-
dc.contributor.authorHolmoy, T.-
dc.contributor.authorWuerfel, J.-
dc.contributor.authorHeer, Y.-
dc.contributor.authorBraune, S.-
dc.contributor.authorBergmann, A.-
dc.contributor.authorZuercher, M.-
dc.contributor.authorLiu, C.-
dc.contributor.authorKuenzel, T.-
dc.contributor.authorMoore, S.-
dc.contributor.authorVollmer, T.-
dc.date.accessioned2022-12-15T08:40:18Z-
dc.date.available2022-12-15T08:40:18Z-
dc.date.issued2022-
dc.date.submitted2022-12-09T12:49:03Z-
dc.identifier.citationMultiple Sclerosis Journal, 28 (S3) , p. 673 -674-
dc.identifier.urihttp://hdl.handle.net/1942/39040-
dc.description.sponsorshipF. Hoffmann-La Roche Ltd; Articulate Science, UK-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.titleOcrelizumab in patients with early-stage RRMS - results from the phase IIIb ENSEMBLE trial and the matched real-world NTD MS registry cohort-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateOCT 26-28, 2022-
local.bibliographicCitation.conferencename38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-
local.bibliographicCitation.conferenceplaceAmsterdam, NETHERLANDS-
dc.identifier.epage674-
dc.identifier.issueS3-
dc.identifier.spage673-
dc.identifier.volume28-
local.format.pages2-
local.bibliographicCitation.jcatM-
local.publisher.place1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.classdsPublValOverrule/internal_author_not_expected-
dc.identifier.isi000866540802365-
local.provider.typewosris-
local.description.affiliation[Hartung, H. -P.] Heinrich Heine Univ Dusseldorf, Dept Neurol, UKD, Ctr Neurol & Neuropsychiat, Dusseldorf, Germany.-
local.description.affiliation[Hartung, H. -P.] LVR Klinikum, Dusseldorf, Germany.-
local.description.affiliation[Hartung, H. -P.] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia.-
local.description.affiliation[Hartung, H. -P.] Palacky Univ Olomouc, Dept Neurol, Olomouc, Czech Republic.-
local.description.affiliation[Holmoy, T.] Akershus Univ Hosp, Dept Neurol, Nordbyhagen, Norway.-
local.description.affiliation[Holmoy, T.] Univ Oslo, Inst Clin Med, Oslo, Norway.-
local.description.affiliation[Wuerfel, J.] Hasselt Univ, Univ MS Ctr, Hasselt, Belgium.-
local.description.affiliation[Heer, Y.; Zuercher, M.] PricewaterhouseCoopers AG, Zurich, Switzerland.-
local.description.affiliation[Braune, S.; Bergmann, A.] NeuroTransData, Neuburg An Der Donau, Germany.-
local.description.affiliation[Liu, C.; Kuenzel, T.; Moore, S.] F Hoffmann La Roche Ltd, Basel, Switzerland.-
local.description.affiliation[Vollmer, T.] Univ Colorado Denver, Dept Neurol, Rocky Mt Multiple Sclerosis Ctr, Anschutz Med Campus, Denver, CO USA.-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.contributorHartung, H. -P.-
item.contributorHolmoy, T.-
item.contributorWuerfel, J.-
item.contributorHeer, Y.-
item.contributorBraune, S.-
item.contributorBergmann, A.-
item.contributorZuercher, M.-
item.contributorLiu, C.-
item.contributorKuenzel, T.-
item.contributorMoore, S.-
item.contributorVollmer, T.-
item.accessRightsOpen Access-
item.fullcitationHartung, H. -P.; Holmoy, T.; Wuerfel, J.; Heer, Y.; Braune, S.; Bergmann, A.; Zuercher, M.; Liu, C.; Kuenzel, T.; Moore, S. & Vollmer, T. (2022) Ocrelizumab in patients with early-stage RRMS - results from the phase IIIb ENSEMBLE trial and the matched real-world NTD MS registry cohort. In: Multiple Sclerosis Journal, 28 (S3) , p. 673 -674.-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Ocrelizumab.pdfPublished version4.68 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.